The new frontier of cancer neuroscience
Understanding complex interactions between cancer and the nervous system may offer new insights into the mechanisms that drive tumour progression
Early signs of progress in osteosarcoma research
Emerging molecular and spatial approaches are providing new insights into osteosarcoma and identifying potential targets for future therapies
ctDNA is unlocking new clinical opportunities for liquid biopsy
Testing standardisation and optimal integration for routine clinical use remain challenging
Overcoming resistance to immunotherapy in NSCLC?
Understanding the evolution of immunotherapy resistance holds the key to developing novel strategies in NSCLC
What is the way forward for undruggable tumour targets?
2026 ESMO TAT Honorary Awardee, Prof. Timothy A. Yap, sees a bright future ahead for novel synthetic lethal strategies, driven by advances in technology and novel biomarkers
Triple combination with radioligand therapy improves radiographic progression-free survival in metastatic prostate cancer
Presidential Symposium presentation provides insights into the role of 177Lu-PSMA-617 in the treatment of hormone-sensitive prostate cancer, with results also presented in castration-resistant disease
How will computational and AI tools guide future anticancer strategies?
Growing evidence shows that AI models can predict a patient's disease trajectory and signal the need for early therapeutic intervention
Studies show two promising new immune-related targets in cancer
Agents targeting B7-H3 and CEACAM6 pass their initial clinical tests, according to results from first-in-human trials
KRAS and TP53 may have a key role in the development of pancreatic cancer
Studies provide new insights into the driver landscape of these gastrointestinal tumours and show improved prediction of patient-specific outcomes.
Melanoma research continues to lead the way in new immunotherapies
For recipient of the ESMO Lifetime Achievement Award, Prof. John Haanen, melanoma research has provided him with a career full of innovation, but there is always more to explore